CRVS

Corvus Pharmaceuticals Inc

NASDAQ: CRVS · HEALTHCARE · BIOTECHNOLOGY

$12.56

+5.46% today

Updated 2026-06-22

Market cap

$1.00B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.55

Dividend yield

—

52W range

$4 – $27

Volume

1.6M

Market cap

$1.00B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.55

Dividend yield

—

52W range

$4 – $27

Volume

1.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-4.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target

$33.33

+165.37%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -4.30 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-10.46M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-41.31M	$-27.03M	$-62.29M	$-15.28M	$-13.69M
EPS	—	—	—	—	$-0.55
Free cash flow	$-27.29M	$-23.97M	$-25.42M	$-32.97M	$-10.46M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-05-18	MILLER, RICHARD A MD	Buy	5,000	$12.05
2026-05-18	MILLER, RICHARD A MD	Buy	1,932	$12.01
2026-04-23	CHAN, ANDREW C.	Buy	30,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CRVS	$1.00B	26	4.3	3.0	5.0	6.5	—	Avoid
LLY	$1.01T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$567.28B	57	4.7	9.0	3.3	6.0	-67.79%	Buy
ABBV	$391.50B	63	4.0	8.0	4.0	5.0	-48.06%	Buy
UNH	$373.28B	54	5.3	5.5	4.0	5.5	-24.80%	Buy
NVS	$289.19B	49	3.3	9.0	3.3	4.5	-62.62%	Hold

Smart narrative

Corvus Pharmaceuticals Inc trades at $12.56. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -4.30, it sits in the distress.

Frequently asked questions

What is Corvus Pharmaceuticals Inc's stock price?

Corvus Pharmaceuticals Inc (CRVS) trades at $12.56.

Is Corvus Pharmaceuticals Inc overvalued?

Corvus Pharmaceuticals Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Corvus Pharmaceuticals Inc (CRVS)?

The 12-month analyst consensus target is $33.33, about 165.4% above the current $12.56. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Corvus Pharmaceuticals Inc's Altman Z-Score is -4.30, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.corvuspharma.com

Quick metrics

P/S ratio—

ROE-18.35%

Beta0.84

50D MA$13.92

200D MA$11.81

Shares out0.08B

Float0.07B

Short ratio—

Avg volume1.6M

Performance

1 week+0.00%

1 month+1.91%

3 months-16.82%

YTD+52.21%

1 year—

3 years—

5 years—

Compare

CRVS vs LLY →CRVS vs JNJ →CRVS vs ABBV →Stock screener →